

\$3m Joint Development Programme with the US Army

Cambridge, England: CMI Ltd, a leading acoustic biosensor technology company, announces that it has successfully taken up a joint development programme with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for the detection of bioterrorism agents.

The programme is supported by \$3 million of core funding from the US National Institute of Allergy and Infectious Diseases (NIAID, part of the US National Institutes of Health).

Under the terms of the collaboration, CMI and USAMRIID will together develop enhanced systems with improved sensitivity and specificity for the detection of key bioterrorism agents. CMI will supply USAMRIID with access to its breakthrough acoustic detection technologies, including proprietary Resonant Acoustic Profiling™ (RAP™) systems. USAMRIID will optimize and develop assays for detection of select bio-threat viruses, bacteria and toxins and will also parallel track development of nucleic acid based assays. This will ultimately lead to a hand-held, low power device that can detect biological agents rapidly and accurately.

Dr. Matthew Cooper, Managing Director of CMI Ltd commented:

"We are very excited to be working with such a prestigious organization as USAMRIID. USAMRIID has produced over 20 candidate medical products during the past decade, and employs the most respected infectious disease and biological defense experts in the world. We are also very grateful to the NIH and the NIAID, who have recognized the power of our approach for the detection of key pathogenic agents that are a threat to both human health and to society in general."

Contacts:

Dr. Matthew Cooper
Managing Director

mcooper@cam-medical.com
+44 (0)1223 225324

USAMRIID contacts:

Caree Vander Linden
Public Affairs

caree.vanderlinden@us.army.mil
+1 (301) 619 2285

About CMI

CMI Ltd, based at the Cambridge Science Park, England, was formed in October 2007 and is dedicated to developing a series of diagnostic devices that will help in the diagnosis of diseases and enable the more efficient monitoring of human health. Our mission is to develop the diagnostic devices to be sold worldwide.

The technology is based on robust label-free diagnostic systems exploiting high frequency acoustics to specifically diagnose disease. The systems can directly detect a range of molecules, bacteria and viruses in both crude samples and complex matrices with minimal need for sample processing or purification.